See up to 3 months of ZYME. The 7-day demo opens the 1M and 3M ranges and puts ZYME on your watchlist.
Start 7-day demoLatest ZYME insider trades
- Adam Schayowitz - OfficerOpen-market sale$358K
Mark Hollywood - OfficerOpen-market sale$139K
About Zymeworks Inc. (ZYME)
Zymeworks Inc. is an SEC registrant, filing under CIK 0001937653, classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
ZYME Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 13,832 | $358K |
| Option exercise | 2 | 74,074 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ZYME insider transactions (Form 4)
8034 Form 4 filings on record, the earliest from Dec 12, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Adam Schayowitz - Officer | Option exercise | Common Stock | 37,037 | $0.00 footnote F1 | - | |
| Adam Schayowitz - Officer | Open-market sale | Common Stock | 13,832 | $25.85 footnote F3 | $358K | |
| Adam Schayowitz - Officer | Option exercise | Restricted Stock Unit | 37,037 | $0.00 | - | |
| ||||||
| Mark Hollywood - Officer | Grant or award | Common Stock | 939 | $22.22 footnote F2 | $21K | |
| ||||||
| Paul R. Schneider - Officer | Grant or award | Stock Option (Right to Buy) | 178,000 | $0.00 | - | |
| Paul R. Schneider - Officer | Grant or award | Restricted Stock Unit | 119,000 | $0.00 | - | |
| Adam Schayowitz - Officer | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Adam Schayowitz - Officer | Grant or award | Restricted Stock Unit | 47,000 | $0.00 | - | |
| Adam Schayowitz - Officer | Grant or award | Performance Stock Unit | 76,000 | $0.00 | - | |
| Scott Platshon - Officer | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Scott Platshon - Officer | Grant or award | Restricted Stock Unit | 47,000 | $0.00 | - | |
| Scott Platshon - Officer | Grant or award | Performance Stock Unit | 76,000 | $0.00 | - | |
| Kristin Stafford - Officer | Grant or award | Stock Option (Right to Buy) | 178,000 | $0.00 | - | |
| Kristin Stafford - Officer | Grant or award | Restricted Stock Unit | 119,000 | $0.00 | - | |
| Kristin Stafford - Officer | Grant or award | Restricted Stock Unit | 50,000 | $0.00 | - | |
| Mark Hollywood - Officer | Option exercise | Common Stock | 17,666 | $0.00 footnote F1 | - | |
| Mark Hollywood - Officer | Open-market sale | Common Stock | 6,120 | $22.67 footnote F3 | $139K | |
| Mark Hollywood - Officer | Option exercise | Restricted Stock Unit | 17,666 | $0.00 | - | |
| Mark Hollywood - Officer | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Mark Hollywood - Officer | Grant or award | Restricted Stock Unit | 47,000 | $0.00 | - | |
| Mark Hollywood - Officer | Grant or award | Performance Stock Unit | 66,000 | $0.00 | - | |
| ||||||
| Brian N. Cherry | Grant or award | Stock Option (Right to Buy) | 23,000 | $0.00 | - | |
| Brian N. Cherry | Grant or award | Restricted Stock Unit | 15,400 | $0.00 | - | |
 Jeffrey T. L. Smith - Officer | Option exercise | Common Stock | 17,666 | $0.00 footnote F1 | - | |
| Jeffrey T. L. Smith - Officer | Open-market sale | Common Stock | 9,310 | $22.67 footnote F3 | $211K | |
| Jeffrey T. L. Smith - Officer | Option exercise | Restricted Stock Unit | 17,666 | $0.00 | - | |
| ||||||
| Gregory Austin Ciongoli | Grant or award | Stock Option (Right to Buy) | 11,500 | $0.00 | - | |
| Gregory Austin Ciongoli | Grant or award | Restricted Stock Unit | 7,700 | $0.00 | - | |
| Kelvin Neu | Grant or award | Stock Option (Right to Buy) | 11,500 | $0.00 | - | |
| Kelvin Neu | Grant or award | Restricted Stock Unit | 7,700 | $0.00 | - | |
| Robert E. Landry | Grant or award | Stock Option (Right to Buy) | 11,500 | $0.00 | - | |
| Robert E. Landry | Grant or award | Restricted Stock Unit | 7,700 | $0.00 | - | |
| Alessandra Cesano | Grant or award | Stock Option (Right to Buy) | 11,500 | $0.00 | - | |
| Alessandra Cesano | Grant or award | Restricted Stock Unit | 7,700 | $0.00 | - | |
| Carlos Campoy | Grant or award | Stock Option (Right to Buy) | 11,500 | $0.00 | - | |
| Carlos Campoy | Grant or award | Restricted Stock Unit | 7,700 | $0.00 | - | |
| Susan Mahony | Grant or award | Stock Option (Right to Buy) | 11,500 | $0.00 | - | |
| Susan Mahony | Grant or award | Restricted Stock Unit | 7,700 | $0.00 | - | |
| Paul Andrew Moore - Officer | Option exercise | Common Stock | 17,666 | $0.00 footnote F1 | - | |
| Paul Andrew Moore - Officer | Open-market sale | Common Stock | 9,560 | $22.67 footnote F3 | $217K | |
| Paul Andrew Moore - Officer | Option exercise | Restricted Stock Unit | 17,666 | $0.00 | - | |
| Paul Andrew Moore - Officer | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Paul Andrew Moore - Officer | Grant or award | Restricted Stock Unit | 47,000 | $0.00 | - | |
| Paul Andrew Moore - Officer | Grant or award | Performance Stock Unit | 66,000 | $0.00 | - | |
| ||||||
| Kenneth Galbraith - Officer | Option exercise | Common Stock | 64,000 | $0.00 footnote F1 | - | |
| Kenneth Galbraith - Officer | Open-market sale | Common Stock | 30,424 | $22.67 footnote F3 | $690K | |
| Kenneth Galbraith - Officer | Option exercise | Restricted Stock Unit | 64,000 | $0.00 | - | |
| Kenneth Galbraith - Officer | Grant or award | Stock Option (Right to Buy) | 216,000 | $0.00 | - | |
| Kenneth Galbraith - Officer | Grant or award | Restricted Stock Unit | 144,000 | $0.00 | - | |
| Kenneth Galbraith - Officer | Grant or award | Performance Stock Unit | 222,000 | $0.00 | - | |
| ||||||
| Leone D. Patterson - Officer | Grant or award | Common Stock | 459 | $10.55 | $5K | |
| Jeffrey T. L. Smith - Officer | Option exercise | Common Stock | 20,000 | $0.00 | - | |
| Jeffrey T. L. Smith - Officer | Open-market sale | Common Stock | 10,538 | $25.10 | $264K | |
| Jeffrey T. L. Smith - Officer | Option exercise | Restricted Stock Unit | 20,000 | $0.00 | - | |
| Kenneth Galbraith - Officer | Option exercise | Common Stock | 47,668 | $0.00 | - | |
| Kenneth Galbraith - Officer | Open-market sale | Common Stock | 22,657 | $25.10 | $569K | |
| Kenneth Galbraith - Officer | Option exercise | Common Stock | 66,666 | $0.00 | - | |
| Kenneth Galbraith - Officer | Open-market sale | Common Stock | 31,686 | $25.10 | $795K | |
| Kenneth Galbraith - Officer | Option exercise | Restricted Stock Unit | 47,668 | $0.00 | - | |
| Kenneth Galbraith - Officer | Option exercise | Restricted Stock Unit | 66,666 | $0.00 | - | |
| Paul Andrew Moore - Officer | Option exercise | Common Stock | 17,168 | $0.00 | - | |
| Paul Andrew Moore - Officer | Open-market sale | Common Stock | 9,289 | $25.10 | $233K | |
| Paul Andrew Moore - Officer | Option exercise | Common Stock | 20,000 | $0.00 | - | |
| Paul Andrew Moore - Officer | Open-market sale | Common Stock | 10,821 | $25.10 | $272K | |
| Paul Andrew Moore - Officer | Option exercise | Restricted Stock Unit | 17,168 | $0.00 | - | |
| Paul Andrew Moore - Officer | Option exercise | Restricted Stock Unit | 20,000 | $0.00 | - | |
| Kenneth Galbraith - Officer | Option exercise | Common Stock | 100,000 | $0.00 footnote F1 | - | |
| Kenneth Galbraith - Officer | Open-market sale | Common Stock | 47,528 | $27.02 footnote F3 | $1.28M | |
| Kenneth Galbraith - Officer | Option exercise | Restricted Stock Unit | 100,000 | $0.00 | - | |
| ||||||
| Gregory Austin Ciongoli | Grant or award | Common Stock | 415,000 | $12.02 | $4.99M | |
| Gregory Austin Ciongoli | Grant or award | Stock Option (Right to Buy) | 62,000 | $0.00 | - | |
| Robert E. Landry | Grant or award | Stock Option (Right to Buy) | 62,000 | $0.00 | - | |
| EcoR1 Capital, LLC - Director | Open-market purchase | Common Stock | 11,958 | $14.12 | $169K | |
| EcoR1 Capital, LLC - Director | Open-market purchase | Common Stock | 16,692 | $14.38 | $240K | |
| EcoR1 Capital, LLC - Director | Open-market purchase | Common Stock | 101,659 | $14.49 | $1.47M | |
| EcoR1 Capital, LLC - 10% Owner | Open-market purchase | Pre-Funded Warrants | 5,086,521 | $9.83 | $50.00M | |
| Derek John Michael Miller | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
| Nancy Davidson | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
| Neil Gallagher | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
| Alessandra Cesano | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
Item 1.01, 2.01, 2.03, 7.01, 9.01
Item 7.01, 8.01, 9.01
Item 2.02, 7.01, 9.01
Item 1.01, 7.01, 9.01
Recent ZYME Form 144 notices of proposed sale
1An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Adam Schayowitz | officer | 13,832 | $349K | View on EDGAR |
ZYME insider trading FAQ
What is the latest insider trade for ZYME?
Zymeworks Inc. (ZYME) had 1 insider filing in the last 90 days, with the most recent on 2026-10-09. The full record for ZYME runs to 34 Form 4 filings, the earliest from 2024-12-12. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ZYME stock?
No insider purchases of ZYME were filed in the last 90 days. 4 purchases are on record for this company.
How many insiders are selling ZYME stock?
1 insider sale of ZYME was filed in the last 90 days, totaling $358K.
Where can I see ZYME SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ZYME Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Adam Schayowitz view on EDGAR
- - Mark Hollywood view on EDGAR
- - Paul R. Schneider view on EDGAR
- - Adam Schayowitz view on EDGAR
- - Scott Platshon view on EDGAR
- - Kristin Stafford view on EDGAR
- - Mark Hollywood view on EDGAR
- - Brian N. Cherry view on EDGAR
- - Jeffrey T. L. Smith view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where ZYME's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ZYME with a 7-day demo
- ZYME on your watchlist
- Every ZYME Form 4 filing on record
- Up to 3 months of ZYME price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
